| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/23/2001 | US6177102 Controlled release dosage form of analgesic such as etodolac, filler, and a carrier base comprising a high molecular weight hydroxypropyl methyl cellulose, optional water insoluble binder, and remainder water soluble binder |
| 01/23/2001 | US6177101 Delavirdine high strength tablet formulation |
| 01/23/2001 | US6177089 Aging resistance of skins by stimulating epidermal renewal |
| 01/23/2001 | US6177087 Administering a polymer conjugate |
| 01/23/2001 | US6177071 Polar solvent-in-oil emulsions and multiple emulsions |
| 01/23/2001 | US6177068 Time release active emulsion a crosslinked a vinyl amide polymer |
| 01/23/2001 | US6177064 Anti-cariogenic activity of erythritol |
| 01/23/2001 | US6177063 Anhydrous aerosol hairspray compositions containing silcone grafted copolymers |
| 01/23/2001 | CA2314473A1 New b-carboline derivatives, a procedure for preparing them and the pharmaceutical compounds containing them |
| 01/23/2001 | CA2296884C Targeted liposomes and methods for liposome-protein coupling |
| 01/23/2001 | CA2219631C Pyrrolidinyl methyl indole salt |
| 01/23/2001 | CA2197451C Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives |
| 01/23/2001 | CA2197272C Pro-drugs of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6- chloro-1,3-dihydro-2h-indol-2-one |
| 01/23/2001 | CA2196885C Carboxamide compounds (changed to n-(2-(pyrrolidinyl-1)-1-phenylethyl) acetamides as kappa receptor antagonists) |
| 01/23/2001 | CA2191790C Biaromatic compounds containing an adamantyl group in para position; pharmaceutical and cosmetic compositions containing them and use thereof |
| 01/23/2001 | CA2128202C Alkyl derivatives of trazodone with cns activity |
| 01/23/2001 | CA2031079C Aminocarbonylcarbamates related to physostigmine, a process for their preparation and their use as medicaments |
| 01/23/2001 | CA2023815C Riboflavin granules containing no inactive ingredient |
| 01/23/2001 | CA2022451C Anti-psychotic piperidynl benzimidazole compounds |
| 01/23/2001 | CA2021340C Cyclic vinylogous n-hydroxy-n-methylureas useful as 5-lipoxygenase inhibitors |
| 01/23/2001 | CA2019717C (1,2,3,4-tetrahydro-9-acridinimino)cyclohexane carboxylic acid and related compounds, a process for their preparation and their use as medicaments |
| 01/22/2001 | CA2746824A1 Neurotherapeutic composition and method |
| 01/22/2001 | CA2312203A1 Cyclobutene derivatives, their preparation and their therapeutic uses |
| 01/20/2001 | WO2001005376A1 New pharmaceutical formulation |
| 01/20/2001 | CA2328102A1 New pharmaceutical formulation |
| 01/18/2001 | WO2001004632A1 Oligosaccharide metabolites of glycosaminoglycans and their use in the diagnosis and treatment of complications of diabetes |
| 01/18/2001 | WO2001004349A2 Method for the diagnosis or the prognosis of alzheimer disease therapeutical composition for preventing or treating alzheimer disease |
| 01/18/2001 | WO2001004341A1 Method for producing oligopolysaccharides |
| 01/18/2001 | WO2001004326A1 Tankyrase homolog protein (thp), nucleic acids, and methods related to the same |
| 01/18/2001 | WO2001004318A2 Myxoma virus genes for immune modulation |
| 01/18/2001 | WO2001004316A2 Antigenic meningococcal peptides |
| 01/18/2001 | WO2001004313A1 Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence |
| 01/18/2001 | WO2001004309A1 T-CELL RECEPTOR η ALTERNATE READING FRAME PROTEIN, (TARP) AND USES THEREOF |
| 01/18/2001 | WO2001004303A1 Compositions corresponding to a calcium transporter and methods of making and using same |
| 01/18/2001 | WO2001004302A1 Atopy gene |
| 01/18/2001 | WO2001004297A2 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 01/18/2001 | WO2001004282A2 Replication-competent anti-cancer vectors |
| 01/18/2001 | WO2001004134A2 Novel esters derived from nucleosides, preparation methods and pharmaceutical compositions containing them |
| 01/18/2001 | WO2001004125A1 Staurosporin derivatives |
| 01/18/2001 | WO2001004124A1 OXATHIEPINO[6,5-b]DIHYDROPYRIDINES, AND RELATED COMPOSITIONS AND METHODS |
| 01/18/2001 | WO2001004122A2 New 2,3-benzodiazepine derivatives |
| 01/18/2001 | WO2001004119A1 Amido spiropiperidines promote the release of growth hormone |
| 01/18/2001 | WO2001004118A2 Quinuclidine derivatives and their use as muscarinic m3 receptor ligands |
| 01/18/2001 | WO2001004116A2 Neurotrophic pyrrolidines and piperidines, and related compositions containing them |
| 01/18/2001 | WO2001004114A1 Diesters of maleic or fumaric acid |
| 01/18/2001 | WO2001004113A2 Process for the preparation of paroxetine and synthetic intermeditates thereof |
| 01/18/2001 | WO2001004112A2 Benzofurane derivatives |
| 01/18/2001 | WO2001004111A1 Anilinoquinazolines as protein tyrosine kinase inhibitors |
| 01/18/2001 | WO2001004106A1 Process for producing dibenzothiazepine derivatives |
| 01/18/2001 | WO2001004102A1 Quinazoline derivatives |
| 01/18/2001 | WO2001004099A1 Benzoylpyridazines |
| 01/18/2001 | WO2001004089A1 Vitamin d3 analogs |
| 01/18/2001 | WO2001003821A1 Method of particle formation |
| 01/18/2001 | WO2001003774A2 Pharmaceutical composition for the treatment of calcification |
| 01/18/2001 | WO2001003743A1 Manipulation of tissue or organ type using the notch pathway |
| 01/18/2001 | WO2001003739A1 Fibrosis inhibitors containing as the active ingredient sphingosine-1-phosphate receptor agonist or sphingosine-1-phosphate |
| 01/18/2001 | WO2001003716A1 Method of treating malignancies and viral infections and improving immune function with a dietary supplement |
| 01/18/2001 | WO2001003713A1 METHOD FOR EXTRACTING RESVERATROL AND/OR ε-VINIFERIN |
| 01/18/2001 | WO2001003712A1 Composition containing extracts of butyrospermum parkii and the use as medicament or dietary supplement |
| 01/18/2001 | WO2001003711A1 Method for isolating lipophilic materials out of vegetable and/or or animal material |
| 01/18/2001 | WO2001003707A1 Heartburn treatment |
| 01/18/2001 | WO2001003705A1 Compositions and methods for raising hdl cholesterol levels |
| 01/18/2001 | WO2001003704A1 Dietary calcium as a supplement to vitamin d compound treatment of multiple sclerosis |
| 01/18/2001 | WO2001003703A1 An oral composition having as a first active ingredient rofleponide and as a second active ingredient an antibiotic, for use in intestinal conditions, especially crohn's disease |
| 01/18/2001 | WO2001003702A1 Pharmaceutical formulations comprising a glucocorticosteroid and an antifungal azole, for increasing the local mucosal tissue concentration of glucocorticosteroids in the gi tract |
| 01/18/2001 | WO2001003701A1 An oral composition having as a first active ingredient budesonide and as a second active ingredient an antibiotic, for use in intestinal conditions, especially crohn's disease |
| 01/18/2001 | WO2001003700A1 Combination of chromium and vanadium for glucose metabolism disorders |
| 01/18/2001 | WO2001003699A1 Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances |
| 01/18/2001 | WO2001003698A1 Taste masked pharmaceutical liquid formulations |
| 01/18/2001 | WO2001003697A1 2-amino-benzoxazinones for the treatment of herpes simplex virus |
| 01/18/2001 | WO2001003696A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 01/18/2001 | WO2001003695A1 Improvement of bioavailability with vitamin c fatty acid esters |
| 01/18/2001 | WO2001003694A1 Treatment of neurotic disorders |
| 01/18/2001 | WO2001003693A1 Pharmaceutical composition containing fenofibrate and preparation method |
| 01/18/2001 | WO2001003692A1 Compositions and methods for promoting nerve regeneration |
| 01/18/2001 | WO2001003690A1 Novel vasodilator cannabinoid analogs |
| 01/18/2001 | WO2001003689A1 Antianxiety drugs |
| 01/18/2001 | WO2001003688A2 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 01/18/2001 | WO2001003685A2 Novel prodrugs for antimicrobial amidines |
| 01/18/2001 | WO2001003684A2 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
| 01/18/2001 | WO2001003683A2 Cardioactive composition comprising l-carnitine and its derivatives and crataegus extracts |
| 01/18/2001 | WO2001003682A2 Use of pyridoxin derivatives for the treatment of diabetes and related complications |
| 01/18/2001 | WO2001003681A2 Use of flavones, coumarins and related compounds to treat infections |
| 01/18/2001 | WO2001003680A2 Compounds for inhibiting diseases and preparing cells for transplantation |
| 01/18/2001 | WO2001003678A2 Transdermal therapeutic system for the utilization of tolterodine |
| 01/18/2001 | WO2001003670A1 Method for controlled production of ultrafine microparticles and nanoparticles |
| 01/18/2001 | WO2001003669A2 Delivery of liposomal-encapsulated antioxidants and applications thereof |
| 01/18/2001 | WO2001003668A1 Pulmonary delivery of liposome-encapsulated cannabinoids |
| 01/18/2001 | WO2001003667A1 Delivery system for biological material |
| 01/18/2001 | WO2001003664A1 Stabilized ascorbic acid, composition, and method of use |
| 01/18/2001 | WO2001003658A1 Crosslinked cationic microgels, process for making same and hair care compositions therewith |
| 01/18/2001 | WO2001003657A1 Topically applied idebenone-containing agent with protective and regenerative effect |
| 01/18/2001 | WO2001003656A1 Antimicrobial artificial nail composition and methods for preparing and using same |
| 01/18/2001 | WO2001003649A2 Compositions and methods for the treatment of parkinson's disease |
| 01/18/2001 | WO2000071516A3 INHIBITORS OF FACTOR Xa |
| 01/18/2001 | WO2000066099A3 Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
| 01/18/2001 | WO2000063225A3 Macrolide antiinfective agents |
| 01/18/2001 | WO2000063224A3 Macrolide antiinfective agents |
| 01/18/2001 | WO2000062793A3 Pseudomycin antifungal compositions and methods for their use |
| 01/18/2001 | WO2000062744A3 Skin care compositions containing combination of skin care actives |